This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, C.-C. Articles by Lau, J. Y. N. Search for Related Content PubMed PubMed Citation Articles by Lin, C.-C. Articles by Lau, J. Y. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1395-1398, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1395-1398.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics and Metabolism of [¹⁴C]Ribavirin in Rats and Cynomolgus Monkeys

Research and Development, Ribapharm Inc., Costa Mesa, California 92626

Received 28 January 2002/ Returned for modification 25 July 2002/ Accepted 21 January 2003

Absorption, pharmacokinetics, distribution, metabolism, and excretion of [¹⁴C]ribavirin were studied in rats (30 mg/kg of body weight) and cynomolgus monkeys (10 mg/kg) after intravenous (i.v.) and oral administration. The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys. After i.v. administration, the elimination half-life (t_[1/2]) was 9.9 h in rats and 130 h in monkeys and the total body clearance was 2,600 ml/h/kg in rats and 224 ml/h/kg in monkeys. The apparent volume of distribution was 11.4 liter/kg in rats and 29.4 liter/kg in monkeys. There was extensive distribution of drug-derived radioactivity into red blood cells and extensive metabolism of ribavirin in rats and a lesser degree of metabolism in monkeys. Excretion of total radioactivity in urine from rats accounted for 84% of the i.v. dose and 83% of the oral dose, whereas that from monkeys accounted for 47% of the i.v. dose and 67% of the oral dose. Several metabolites were observed in plasma and urine from both species. The amount of unchanged ribavirin in urine from both species was quite small after either i.v. or oral administration.

This article has been cited by other articles:

• Lin, C.-c., Xu, C., Zhu, N., Yeh, L.-T. (2006). Absorption, Metabolism, and Excretion of [14C]Viramidine in Humans.. Antimicrob. Agents Chemother. 50: 2368-2373 [Abstract] [Full Text]  
• Lin, C.-C., Lourenco, D., Xu, G., Yeh, L.-T. (2004). Disposition and Metabolic Profiles of [14C]Viramidine and [14C]Ribavirin in Rat and Monkey Red Blood Cells and Liver. Antimicrob. Agents Chemother. 48: 1872-1875 [Abstract] [Full Text]  
• Lin, C.-C., Luu, K., Lourenco, D., Yeh, L.-T. (2003). Pharmacokinetics and Metabolism of [14C]Viramidine in Rats and Cynomolgus Monkeys. Antimicrob. Agents Chemother. 47: 2458-2463 [Abstract] [Full Text]